RxPG News : Clinical Trials

Adipose-derived stem cells as a therapy for cardiovascular diseases ?

Sun, 11 Feb 2007 12:45:55 PST

Cytori Therapeutics (NASDAQ:CYTX) (FWB:XMPA) and Hospital Gregorio Maranon in Madrid, Spain treated the first patient in Cytori's randomized clinical trial investigating the safety and feasibility of adipose-derived stem and regenerative cells as a therapy for cardiovascular disease.

Pre hypertension best managed by early pharmacological intervention

Sun, 19 Mar 2006 02:43:00 PST

Patients experiencing high normal blood pressure (HNBP), a precursor to hypertension, may benefit from early treatment with pharmacological therapy, according to new research presented today at the American College of Cardiology's 55th Annual Scientific Session. HNBP, often referred to as "prehypertension," is associated with double the normal risk of heart attacks and strokes. ACC.06 is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine.

Patients should not discontinue clopidogrel without consultation

Sat, 18 Mar 2006 02:40:00 PST

Recent media reports regarding the results of the CHARISMA Trial may be misinterpreted by patients with coronary stents and other conditions*, causing these patients to inappropriately stop taking the anti-clotting drug clopidogrel (Plavix®). Patients taking Plavix® for any reason should consult with their cardiologist or other health care provider before stopping this medication.

Clopidogrel and aspirin combination fails to show long term beneficial affects in stable vascular patients

Sat, 18 Mar 2006 02:17:00 PST

While the CHARISMA trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance) results have shown no benefit overall of the combination of Clopidogrel and aspirin in the long term in stable vascular patients, and some indication of harm in patients in primary prevention, the ESC would like to remind patients that dual antiplatelet therapy is an essential, approved and recommended therapy for one year in patients post ACS without ST-segment elevation, and for at least six months post stenting.

Bluhm Cardiovascular Institute Surgeons Implant Heart Pump in Comparative Study of Two Devices

Sat, 19 Nov 2005 02:01:00 PST

Chicago's first participant in the RELIANT (Randomized Evaluation of the Novacor(r) LVAS In A Non-Transplant Population) research study recently went home from Northwestern Memorial Hospital.

Ground-breaking heart stem cell trial (REGENERATE) now underway

Thu, 13 Oct 2005 15:25:00 PST

Doctors at Barts and The London NHS Trust have launched the UKs first large-scale clinical trial designed to find out if a patients own stem cells can be used to treat heart disease. The ground-breaking research, which is being funded by the Heart Cells Foundation charity, will involve 700 patients over the next four years. The trial is made up of three randomised-controlled studies. The first study will involve 300 patients whose hearts are failing because of heart disease or a previous heart attack. The second study will involve 200 patients whose hearts are failing specifically because of dilated cardiomyopathy a heart muscle disorder. The third study will involve 200 patients who have just had a heart attack.